1,373 results on '"Voest, Emile"'
Search Results
2. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
3. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
4. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
5. Agnostic drug development revisited
6. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
7. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
8. Functional precision oncology using patient-derived assays: bridging genotype and phenotype
9. A pan-cancer analysis of the microbiome in metastatic cancer
10. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
11. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
12. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
13. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity
14. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
15. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
16. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
17. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)
18. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
19. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
20. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
21. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
22. Delivering precision oncology to patients with cancer
23. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
24. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
25. Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
26. Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
27. Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
28. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
29. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
30. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma:Results From the Drug Rediscovery Protocol
31. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
32. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
33. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
34. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
35. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer:Results from the drug rediscovery protocol (DRUP)
36. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
37. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
38. Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
39. Facilitating a culture of responsible and effective sharing of cancer genome data
40. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
41. Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics
42. Caring for patients with cancer in the COVID-19 era
43. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
44. Tumor organoid–T-cell coculture systems
45. Pan-cancer whole-genome analyses of metastatic solid tumours
46. When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward
47. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
48. Precision cancer medicine: Concepts, current practice, and future developments
49. Abstract IA013: A zebrafish model for VHL and hypoxia signaling
50. Is It Our Duty To Hunt for Pathogenic Mutations?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.